Play all audios:
CORRECTION TO: _Bone Marrow Transplantation_ advance online publication, 29 July 2013; doi:10.1038/bmt.2013.107 Since the publication of this article the authors have noticed an error in
Table 1 under the section _Treatment of GVHD._ The dose of budesonide has been given as 9 mg/kg/day. It should be 9 mg/day. The corrected section appears below. _Treatment of GVHD_
Treatment of acute GVHD First-line treatment The first-line treatment of acute GVHD is MP. Treatment is initiated for acute GVHD of grade II or higher. The initial MP dose is 2 mg/kg/day.
MP is given in two divided doses per day. The initial dose is continued for 7 days. Treatment can be changed in case of clear progression after 5 days, but there is no evidence that
change in treatment will affect the outcome. No reduction of the dose is done during the first 7 days. Tapering of the dose is done slowly and depending on the response. No marked dose
reductions are done in the early phase. MP is not discontinued before all signs of GVHD have disappeared. Failure of treatment (corticosteroid resistance) is defined as no response after 7
days of treatment or clear progression after 5 days. Non-absorbable oral steroid (budesonide) is given, along with systemic corticosteroid, for Gl GVHD in the dose of 9 mg/day in one daily
dose p.o. Topical steroids are used for skin GVHD according to centre policy. The decision to initiate treatment is based on clinical signs. Skin biopsy before initiation of treatment is
recommended, but the decision to treat should not depend on the biopsy result. The same recommendation applies to upper Gl or sigmoid biopsy if Gl manifestation is suspected. This error also
occurred in the sentence below, this has now been corrected. Non-absorbable oral steroid treatment (budesonide 9 mg/day) is recommended along with systemic therapy in the case of
gastrointestinal GVHD. Budesonide and beclomethasone are both being used for gastrointestinal GVHD; they have different pharmacological characteristics and might have different effects on
upper or lower gastrointestinal tract GVHD. There are no comparative studies to date; hence budesonide is recommended in the absence of a prospective trial. The authors would like to
apologize for any inconvenience caused. AUTHOR INFORMATION Authors * T Ruutu View author publications You can also search for this author inPubMed Google Scholar * A Gratwohl View author
publications You can also search for this author inPubMed Google Scholar * T de Witte View author publications You can also search for this author inPubMed Google Scholar * B Afanasyev View
author publications You can also search for this author inPubMed Google Scholar * J Apperley View author publications You can also search for this author inPubMed Google Scholar * A
Bacigalupo View author publications You can also search for this author inPubMed Google Scholar * F Dazzi View author publications You can also search for this author inPubMed Google Scholar
* P Dreger View author publications You can also search for this author inPubMed Google Scholar * R Duarte View author publications You can also search for this author inPubMed Google
Scholar * J Finke View author publications You can also search for this author inPubMed Google Scholar * L Garderet View author publications You can also search for this author inPubMed
Google Scholar * H Greinix View author publications You can also search for this author inPubMed Google Scholar * E Holler View author publications You can also search for this author
inPubMed Google Scholar * N Kröger View author publications You can also search for this author inPubMed Google Scholar * A Lawitschka View author publications You can also search for this
author inPubMed Google Scholar * M Mohty View author publications You can also search for this author inPubMed Google Scholar * A Nagler View author publications You can also search for this
author inPubMed Google Scholar * J Passweg View author publications You can also search for this author inPubMed Google Scholar * O Ringdén View author publications You can also search for
this author inPubMed Google Scholar * G Socié View author publications You can also search for this author inPubMed Google Scholar * J Sierra View author publications You can also search for
this author inPubMed Google Scholar * A Sureda View author publications You can also search for this author inPubMed Google Scholar * W Wiktor-Jedrzejczak View author publications You can
also search for this author inPubMed Google Scholar * A Madrigal View author publications You can also search for this author inPubMed Google Scholar * D Niederwieser View author
publications You can also search for this author inPubMed Google Scholar CONSORTIA A WORKING GROUP OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (EBMT) AND THE EUROPEAN
LEUKEMIANET (ELN) ADDITIONAL INFORMATION The online version of the original article can be found at 10.1038/bmt.2013.107 RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE
CITE THIS ARTICLE Ruutu, T., Gratwohl, A., de Witte, T. _et al._ Erratum: Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice. _Bone Marrow
Transplant_ 49, 319 (2014). https://doi.org/10.1038/bmt.2013.210 Download citation * Published: 23 December 2013 * Issue Date: February 2014 * DOI: https://doi.org/10.1038/bmt.2013.210 SHARE
THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to
clipboard Provided by the Springer Nature SharedIt content-sharing initiative